21 September 2017
This webinar explored out of domain (Q)SAR predictions for the ICH M7 mutagenic impurity use-case.
The regulatory and industry speakers were Naomi Kruhlak, U.S. FDA and Michelle Kenyon, Pfizer.
Naomi described the current thinking on how to deal with out of domain (Q)SAR Predictions for ICH M7 before passing on to Michelle who provided an industry perspective.
A recording and slides from this webinar can be found via the link below.